Navigation Links
NHP Reports 2009 First Quarter Results
Date:5/7/2009

First Quarter Highlights

- Upgraded by Fitch to BBB

- Upgraded by Moody's to Baa2

- Standard & Poors Upgrade Outlook to Positive

- Balance Sheet Remains Strong With Modest Capital Commitments Through July 2011

- Maintaining Quarterly Cash Dividend of $0.44 per Share

- Diluted FFO Payout Ratio of 77%

NEWPORT BEACH, Calif., May 7 /PRNewswire-FirstCall/ -- Nationwide Health Properties, Inc. (NYSE: NHP) today announced results of operations for the first quarter ended March 31, 2009. Contemporaneously with this press release, the Company has filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009 with the Securities and Exchange Commission.

"In the current economic environment, the balance sheet is center stage with premiums placed on low leverage and ample liquidity. As evidenced by recent credit rating upgrades from Moody's and Fitch, NHP's balance sheet is strong. On an enterprise value basis, our leverage is a conservative 40% and we have ample liquidity with about $80 million of cash and the full capacity of our $700 million credit facility," commented Douglas M. Pasquale, NHP's Chairman and Chief Executive Officer. "We believe the investment environment favors patience and the difficult economy requires extra attention allocated to our existing assets and tenants. In time we believe that assets will be available at attractive prices, and we expect to make excellent investments as opportunities present themselves," Mr. Pasquale added.

FIRST QUARTER 2009 RESULTS OF OPERATIONS

The following table presents selected unaudited financial information for the first quarter and the year ended March 31, 2009 as compared to th
'/>"/>

SOURCE Nationwide Health Properties, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
2. PLC Systems Reports First Quarter 2009 Results
3. Perrigo Reports Record Third Quarter
4. Symmetry Medical Reports First Quarter 2009 Financial Results
5. Orchid Cellmark Reports Improved First Quarter 2009 Financial Results
6. Labopharm Reports Results for First Quarter Fiscal 2009
7. Isis Reports Strong Financial Results and Highlights for First Quarter of 2009
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Stereotaxis Reports First Quarter 2009 Financial Results
10. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
11. The Ensign Group Reports First Quarter 2009 Earnings of $0.38 per Share; Reaffirms 2009 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... At this initial launch, the ... health information around medical conditions that individuals face, ... as well as helping them find solutions to ... conditions using evidenced based information in print and ... around them., ,     Diabetes, , ...
(Date:3/29/2015)... North American Seminars receives Texas Board Physical Therapy ... . , Utilizing Pilates to Enhance Rehab ... # 56399TX      , The Interactive Shoulder Algorithm ... 10.5 hours - Texas Board of Physical Therapy      ... the SI Joint - 10 hours - Texas Board ...
(Date:3/28/2015)... 2015 Coffee could not only perk you ... from gum disease, researchers have found. , They found that ... Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, then, ... Boston Univ. Henry M. Goldman School of Dental Medicine explored ... issue of the Journal of Periodontology. , “This is the ...
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
Breaking Medicine News(10 mins):Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2
... used farm practice of grafting watermelon and other melon plants ... certain pesticides in the melon fruit, scientists are reporting in ... in the fruit in the study, the scientists advise that ... in a report that appears in ACS, Journal of ...
... block the growth of blood vessels were found to increase ... mice, suggesting a possible explanation for why these drugs don,t ... researchers at the University of Michigan Comprehensive Cancer Center. ... potential breast cancer treatments. But while they do shrink tumors ...
... 24 (HealthDay News) -- Getting too little sleep can make you ... study suggests. The team at Uppsala University in Sweden used ... while they looked at images of food. This was done on ... a night without sleep. The results showed that a specific ...
... -- After studying data on more than 3,700 pairs of ... weight was associated with more than triple the risk for ... affected one of the children. "That only one twin ... twin pairs suggests that environmental factors may play a role ...
... Only about one in five American adults aged 36 to ... epidemic of 2009-2010, even though about 65 percent were at ... claimed to follow the issue moderately or very closely. ... how this age group monitored the epidemic and what they ...
... competitive for scarce funding, scientific journals are increasing efforts ... Still, it may take years to identify and retract ... researchers. "We need a better system," said ... at Virginia Tech. Garner discussed the problem and solution ...
Cached Medicine News:Health News:Avastin, Sutent increase breast cancer stem cells, U-M study shows 2Health News:Can Low Birth Weight Raise Autism Risk? 2Health News:How Did Generation X Respond to the H1N1 'Swine' Flu Epidemic? 2Health News:Scientific plagiarism: A growing problem in an era of shrinking research funding 2
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... March 27, 2015 According to ... (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, ... Indication (AF, VT, WPW) - Global Forecasts to 2019 ", ... to reach around ~$4.73 Billion by 2019 with a ... to 2019. Browse   90   ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... SUNNYVALE, California, September 23, 2010, ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Reata Pharmaceuticals Announce Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Medicine Technology:Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 2Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 3Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 4Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 5Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 6Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 7Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 8Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 9Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 10Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
Straight shafts with 2.0 mm, 1 x 2 Elschnig style teeth. Serrated handle with polished finish. Handle: Wide....
Curved shafts with micro Pierse type tips. Flat open serrated handle with dull finish....
Colibri style 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Medicine Products: